Verismo Therapeutics, Inc

Carisma Therapeutics Inc. is a Philadelphia-based biotech company that is revolutionizing cancer treatment through the development of CAR-Macrophages, a groundbreaking approach to immunotherapy. By engineering monocytes and macrophages to attack tumors, Carisma's innovative cellular therapies have the potential to deliver long-term anti-tumor immunity and significantly improve patient outcomes. With a focus on leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy, Carisma's unique therapeutic approach engages both the innate and adaptive immune systems to launch a multi-pronged attack on tumors. By addressing key challenges faced by current cell therapies, such as tumor infiltration, immunosuppressive tumor microenvironments, and antigen heterogeneity, Carisma is at the forefront of developing life-changing treatments for patients with cancer and other serious disorders.Generated from the website

Aum Biotech, LLC is a cutting-edge biotechnology company based in Philadelphia, PA, specializing in RNA silencing products for cellular and animal studies. Their innovative FANA technology offers a single-step guaranteed knockdown without the need for transfection reagents, making it ideal for a wide range of applications. With a focus on mRNA knockdown, miRNA inhibition, lncRNA knockdown, and viral RNA knockdown, Aum Biotech's AUMsilence, AUMantagomir, AUMlnc, and AUMsilence V products provide efficient and reliable solutions for translation blocking. Backed by a range of publications, testimonials, and protocols, Aum Biotech is at the forefront of RNA silencing research and development.Generated from the website

Mebias Discovery is a Philadelphia-based company specializing in innovative drug discovery and development, with a focus on G Protein Coupled Receptors (GPCRs). Their proprietary membrane protein-NMR drug discovery platform enables the identification of highly selective molecules that bind to GPCR targets, eliminating adverse effects and maximizing therapeutic potential. With seven years of experience, Mebias Discovery has successfully validated their unique drug discovery platform and identified an FDA-approved Investigational New Drug for the mu-opioid receptor. Additionally, they are currently developing Sphingosine 1-phosphate receptor agonists for the treatment of neuropathic pain.Generated from the website